STOCKS TELEGRAPH

Tag: Vigil Stock

  • Vigil Neuroscience (VIGL) Stock Soars After Sanofi’s Acquisition Bid

    Vigil Neuroscience (VIGL) Stock Soars After Sanofi’s Acquisition Bid

    After the news broke that Vigil Neuroscience, Inc. (NASDAQ: VIGL) will be acquired by Sanofi (NASDAQ: SNY), the stock value of the firm surged. At $7.91 as of the most recent trading session, VIGL shares had surged 242.64%. Following a definitive merger agreement between the two companies, there was a sharp stock-price rise.

    Terms of Acquisition and Benefits to Shareholders

    Sanofi would pay $8.00 per share in cash for all of Vigil Neuroscience’s outstanding common shares, which, when fully diluted, would equal around $470 million in equity value.

    Vigil shareholders will receive a $2.00 non-transferable Contingent Value Right (CVR) per share in addition to the upfront payment. This extra payment is subject upon the first commercial sale of VIGL’s main experimental treatment, VG-3927, within a predetermined window of time. The entire transaction value might be around $600 million if it is fulfilled.

    VG-3927 and Alzheimer’s Research Advancements

    The purchase is anticipated to hasten the development of VG-3927, a TREM2 agonist being developed for Alzheimer’s disease, and is consistent with Sanofi’s strategy focus on neurology. In order to restore neuroprotective capabilities that have been compromised in Alzheimer’s disease and other neurodegenerative diseases, VG-3927 addresses microglial activation.

    In order to slow the course of dementia, TREM2 activation may improve microglial phagocytosis, migration, and survival. The clinical development and possible commercialization of VG-3927 are expected to be supported by Sanofi’s strong R&D infrastructure and worldwide footprint.

    Closing Timeline and Shared Mission

    Vigil expects the transaction to close in the third quarter of 2025, subject to customary closing conditions. Both companies emphasized their shared mission of delivering innovative therapies to address unmet medical needs, particularly in neurodegenerative diseases.

    Exclusion of VGL101 from the Deal

    Notably, Vigil’s monoclonal antibody program Iluzanebart (VGL101) is excluded from the acquisition. Prior to the completion of the deal, the exclusive licensing agreement with Amgen—original licensor of VGL101—will be terminated, and the program will be returned to Amgen.

  • Vigil Neuroscience (VIGL) Stock Rises After Promising Alzheimer’s Data

    Vigil Neuroscience (VIGL) Stock Rises After Promising Alzheimer’s Data

    Shares of Vigil Neuroscience, Inc. (NASDAQ: VIGL) experienced a significant upswing today, climbing 12.26% to $2.28, following the release of promising data from its Phase 1 clinical trial evaluating VG-3927 as a potential treatment for Alzheimer’s disease (AD). The company currently holds a “Buy” rating and an ST score of 35 within the Biotechnology industry. While other companies, such as ADMA and ATHE, possess higher ST scores of 52 and 49 respectively, visit screener link to get detailed insight.

    Clearing the Path for the Phase 2 Trial

    Vigil Neuroscience reported encouraging results from their Phase 1 clinical study that evaluated VG-3927. The thorough evaluation of VG-3927’s safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) characteristics lends credence to its progression into a Phase 2 clinical study as a possible once-daily oral treatment for AD. This encouraging evidence supports VG-3927’s further research as a possible therapy for AD of the future generation.

    VG-3927: A Potential Next-Generation Alzheimer’s Therapy

    As the first and only Phase 2-ready oral, once-daily small molecule TREM2 agonist, VG-3927 is designed to provide a differentiated profile that extends beyond targeting amyloid plaques. It aims to address additional factors contributing to disease progression and offers a potentially more convenient treatment regimen for individuals affected by this debilitating condition.

    Key Clinical Trial Findings

    The study demonstrated high brain penetration with a favorable and predictable PK profile supporting once-daily dosing. A robust and dose-dependent reduction of soluble TREM2 (sTREM2) of up to approximately 50% in the cerebrospinal fluid (CSF) was observed, demonstrating a strong PK/PD relationship, sustained target engagement, and TREM2 agonist activity.

    The observed PK and sTREM2 reduction in the AD cohort was consistent with healthy volunteers and similar across evaluated TREM2 and ApoE genetic variants, supporting development in AD across genotypes. Furthermore, the PK and sTREM2 reduction observed in the elderly cohort also aligned with results from healthy volunteers.

    Clinical and in vivo preclinical findings together verify that VG-3927 activates microglia in a neuroprotective manner downstream of TREM2 signaling. Based on these results, the company intends to initiate a Phase 2 trial in the third quarter of 2025, using a 25mg once-daily oral dose.